Market Data 
Markets
Replies to post #145144 on Biotech Values
07/09/12 7:15 PM
Along with its U.S. plans, Ranbaxy is working to expand generic sales in emerging markets. Those are heavily populated countries with a growing middle class and rising government spending on health care, from India and China to Brazil and Russia.
07/12/12 9:06 AM
07/17/12 1:00 PM
The acquisition is intended to make Thermo Fisher a global player in organ transplant products. One Lambda, based in Canoga Park, Calif., makes tests that identify compatible organ donors and recipients, and that detect antibodies which signal the body’s potential rejection of a transplanted organ.
Marc Casper, chief executive, said the acquisition will help Thermo Fisher meet steadily growing demand for organ transplant diagnostic systems in developing economies, a $480 million worldwide market.
“We’re seeing accelerating growth in Brazil and China,” said Casper. “As those health systems become more mature, things like transplantation become more available.”
[Cowen’s Doug] Schenkel called the acquisition price reasonable, but warned that One Lambda’s long-term future may not be so rosy, because new gene sequencing technologies now under development could supplant its donor compatibility tests in five to 10 years.
07/18/12 9:07 AM
07/26/12 10:30 PM
Health experts say China has now caught up to speed with—and even exceeded—the lifestyle-related health problems of more developed countries, and doesn't have sufficient measures in place to prevent diseases such as heart disease, diabetes and cancer, which are costly to treat.
“The country is struggling to deal with a population that is urbanizing, aging and is afflicted with chronic diseases,” said Wang Linhong, the executive deputy director of the chronic-disease arm of the Chinese Center for Disease Control and Prevention.
…Out of every 100 deaths in China, 85 are now caused by chronic diseases, according to China's Ministry of Health. By comparison, the U.S. Centers for Disease Control and Prevention says the rate is 70 per 100 in the U.S., while the World Health Organization says they represent 63% of deaths world-wide.
07/31/12 10:50 AM
08/02/12 11:37 AM
Covidien, a leading global provider of healthcare products, today announced the official opening of its China Technology Center (CTC) Research and Development (R&D) facility in Shanghai. The CTC has two core focus areas:
• Design of Tailored Products: identify and develop products that are customized to meet the needs of China and other Emerging Markets.
• Discovery of Breakthrough Platforms in medical technology –utilize the unique skillsets and expertise of employees in Asia to create and develop new medical device technologies.
…The CTC complements Covidien’s other operations in China, which include 10 commercial offices, a manufacturing center and training facilities for healthcare professionals.
08/05/12 9:08 PM
In China, the report estimates, drug spending will amount to about $121 a person in 2016, which is far less than the $892 a person expected to be spent in the United States. But given that two-thirds of the world’s population lives in those emerging markets, even modest increases can make a big difference.
Spending is expected to double in these markets in the next five years, growing by a projected range of $150 billion to $165 billion, the report found. By 2016, 30 percent of global spending on medicines will be in the emerging markets, compared with 20 percent in 2011.
10/02/12 7:23 PM
10/15/12 9:55 PM
10/31/12 1:25 PM
11/26/12 8:10 AM
The company is expected to tell government and NHS representatives that the UK is failing to keep up with emerging economies in terms of pharmaceutical competitiveness and is risking jobs and investment going overseas…
…Novartis has already downsized in the UK, with cutbacks at its manufacturing and R&D facility in Horsham announced last year affecting 550 jobs, although it has committed to keeping part of the site open, including its respiratory R&D operations.
…In a speech due to be delivered tomorrow, [NVS CFO] Symonds is expected to say that Novartis has made considerable investments in recent years in China, Russia and Brazil because these countries "have each recognised the need to shift from being a consumer of innovation to a generator of innovation".
11/26/12 8:15 AM
GlaxoSmithKline Plc plans to spend more than $1 billion to raise stakes in its Indian and Nigerian consumer healthcare arms, as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health footprint.
… GSK said on Monday it will buy up to an additional 31.8 percent stake in India's GlaxoSmithKline Consumer Healthcare Ltd for about $940 million by paying 3,900 rupees ($70.16) per share in an open offer. The price was a premium of 28 percent to the stock's Friday close.
On similar lines, GSK also said it plans to raise the stake in its Nigerian consumer products unit to 80 percent from 46.4 percent now in a $98 million deal.
Post the offer, GSK's stake in the Indian consumer products arm, which makes health drinks and over-the-counter drugs and balms, will rise to 75 percent from 43.2 percent.
04/18/13 5:12 PM
AI
